Technologies for Treating Cartilage Tissue Loss Following Traumatic Injury

Award Information
Agency: Department of Defense
Branch: Defense Health Program
Contract: W81XWH-11-C-0071
Agency Tracking Number: O2-1236
Amount: $729,999.00
Phase: Phase II
Program: SBIR
Awards Year: 2012
Solicitation Year: 2010
Solicitation Topic Code: OSD10-H04
Solicitation Number: 2010.3
Small Business Information
SpherIngenics, Inc.
800 E Leigh St Ste 51, Suite 51, Richmond, VA, 23219
DUNS: 808554526
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Anthony Nicolini
 Research and Development
 (404) 520-6226
 anicolini@spheringenics.com
Business Contact
 L. Bost
Title: President and CEO
Phone: (404) 385-2115
Email: fbost@spheringenics.com
Research Institution
 Stub
Abstract
Phase I studies demonstrate that human adipose stem cells (ASCs) exhibit characteristics of chondrocytes when cultured in chondrogenic media (CM) and this is enhanced when they are first encapsulated in low viscosity, high mannuronate content alginate beads that are less than 200fYm in diameter containing 250 cells/bead. The microencapsulated cells express mRNAs for factors associated with chondrogenesis and secrete these factors into their media, suggesting that they will also do so in vivo. There are a number of questions remaining that must be addressed in order to move this technology to clinical application. Phase II research will demonstrate whether CM-treated microencapsulated ASCs will enhance cartilage repair and regeneration of craniofacial chondral defects in vivo. We propose to optimize processing conditions for chondrogenic growth factor production by determining if shorter CM-treatments are sufficient and if chondrogenic growth factor production varies among donors; identify the best processing protocol using a small rodent screening model by determining if CM-pretreatment time alters chondrogenic potential of microencapsulated ASCs in vivo and if donor variability is a factor; and test the ability of CM-treated microencapsulated ASCs will repair and regenerate craniofacial cartilage by assessing effectiveness in rabbit critical size auricular and nasal defects.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government